When it come to stem cell....professor Slavin is "Top Dog"

When it come to stem cell....professor Slavin is one of the "Top Dogs"


To Friends and Family…..please forgive……I invited some people from MSWorld to come and take a look here at this next post.

Who knows……I may even meet some of these MSWorld people.
(unlike PLM,……..People cannot email each other or share links to websites pertaining to the disease at MSWorld. (dumb guidelines if you ask me)

I don’t think Professor Slavin liked having his publications questioned half a world away…….(The BRI in downtown Seattle last Friday)

Sometimes it’s so easy to say of another’s work:

…….”Nope”…..”Won’t work”…..”Can’t do that”…..”It’ll never happen”…….”Danger”…….”Risky”…….

I think doctors say it all the time to avoid a liability issue.

Then there is the few that say:
……”it could”…….”why wouldn’t it work”…..”What if we did this”……

I think this is what Professor Slavin and I have in common.

Here is some light reading for you: (Don’t forget that Wikipedia link I gave you the other day)
First,…………..his email to me in regards to my BRI synopsis from last Friday.

The Professor writes:

Dear Todd,

Thanks for the information regarding stem cell activities in other locations. In your email you mentioned re Dr. Nepom commenting that “Professor Slavin had not published any data in a while regarding this procedure”.

I would greatly appreciate if you could tell Dr. Nepom that not only have we pioneered the use of mesenchymal stromal stem cells for the treatment of multiple sclerorsis, amyotrophic lateral sclerosis, spinal injury and some related clinical syndromes, but we also have several publications on the role of stem cells for the treatment of neurological disorders, one that was already sent to the New England J Medicine. In fact, we wrote the first paper on the subject suggesting first in a pre-clinical animal model in mice that treatment with stem cells may be of benefit for such patients and subsequently pioneered similar application in clinical practice.

Attached please find a list of publications that Dr. Neopom could look over on PubMed, and I would be happy to hear his response after reading the contents of this list.

Thanks again for providing us with this interesting information.

Shimon Slavin, M.D.
Professor of Medicine
Scientific & Medical Director
The International Center for Cell Therapy & Cancer Immunotherapy (CTCI)
Tel Aviv Medical Center & Top Ichilov at the Weizman Center

He then attaches a word document with the following links:
(you may need to cut and paste the “HTTP” links below into your web browser)

Items 1 – 16 of 16

1: Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis.
Kassis I, Grigoriadis N, Gowda-Kurkalli B, Mizrachi-Kol R, Ben-Hur T, Slavin S, Abramsky O, Karussis D.
Arch Neurol. 2008 Jun;65(6):753-61.
PMID: 18541795 [PubMed – indexed for MEDLINE]


2: The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders.
Slavin S, Kurkalli BG, Karussis D.
Clin Neurol Neurosurg. 2008 Nov;110(9):943-6. Epub 2008 Mar 6. Review.
PMID: 18325660 [PubMed – indexed for MEDLINE]


3: CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice.
Naor D, Nedvetzki S, Walmsley M, Yayon A, Turley EA, Golan I, Caspi D, Sebban LE, Zick Y, Garin T, Karussis D, Assayag-Asherie N, Raz I, Weiss L, Slavin S, Golan I.
Ann N Y Acad Sci. 2007 Sep;1110:233-47. Review.
PMID: 17911438 [PubMed – indexed for MEDLINE]


4: Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases.
Karussis D, Kassis I, Kurkalli BG, Slavin S.
J Neurol Sci. 2008 Feb 15;265(1-2):131-5. Epub 2007 Jul 3. Review.
PMID: 17610906 [PubMed – indexed for MEDLINE]


5: Neuroprotection in multiple sclerosis.
Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S, Abramsky O.
Clin Neurol Neurosurg. 2006 Mar;108(3):250-4. Epub 2006 Jan 4. Review.
PMID: 16413962 [PubMed – indexed for MEDLINE]


6: Hematopoietic stem cell transplantation for multiple sclerosis.
Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R.
Arch Neurol. 2005 Jun;62(6):860-4. Review. No abstract available.
PMID: 15956156 [PubMed – indexed for MEDLINE]


7: Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures.
Karussis D, Slavin S.
J Neurol Sci. 2004 Aug 15;223(1):59-64. Review.
PMID: 15261562 [PubMed – indexed for MEDLINE]


8: Immunomodulation of autoimmunity in MRL/lpr mice with syngeneic bone marrow transplantation (SBMT).
Karussis DM, Vourka-Karussis U, Lehmann D, Abramsky O, Ben-Nun A, Slavin S.
Clin Exp Immunol. 1995 Apr;100(1):111-7.
PMID: 7697909 [PubMed – indexed for MEDLINE]


9: Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice.
Vourka-Karussis U, Karussis D, Ackerstein A, Slavin S.
Exp Hematol. 1995 Mar;23(3):196-201.
PMID: 7875238 [PubMed – indexed for MEDLINE]


10: Immunomodulation of autoimmunity by linomide.
Karussis DM, Lehmann D, Slavin S, Kalland T, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Abramsky O.
Isr J Med Sci. 1995 Jan;31(1):38-41. No abstract available.
PMID: 7836046 [PubMed – indexed for MEDLINE]


11: Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Ben-Nun A, Kalland T, Abramsky O.
Ann Neurol. 1993 Nov;34(5):654-60.
PMID: 8239559 [PubMed – indexed for MEDLINE]


12: Prevention and reversal of adoptively transferred, chronic relapsing experimental autoimmune encephalomyelitis with a single high dose cytoreductive treatment followed by syngeneic bone marrow transplantation.
Karussis DM, Vourka-Karussis U, Lehmann D, Ovadia H, Mizrachi-Koll R, Ben-Nun A, Abramsky O, Slavin S.
J Clin Invest. 1993 Aug;92(2):765-72.
PMID: 7688762 [PubMed – indexed for MEDLINE]


13: Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).
Karussis DM, Lehmann D, Slavin S, Vourka-Karussis U, Mizrachi-Koll R, Ovadia H, Kalland T, Abramsky O.
Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6400-4.
PMID: 8341645 [PubMed – indexed for MEDLINE]


14: Immunohematopoietic reconstitution by allogeneic and autologous bone marrow grafts as a means for induction of specific unresponsiveness to donor-specific allografts and modified self in autoimmune disorders.
Slavin S, Karussis D, Weiss L, Vourka-Karussis U, Abramsky O.
Transplant Proc. 1993 Feb;25(1 Pt 2):1274-5. No abstract available.
PMID: 8442110 [PubMed – indexed for MEDLINE]


15: Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation.
Karussis DM, Slavin S, Ben-Nun A, Ovadia H, Vourka-Karussis U, Lehmann D, Mizrachi-Kol R, Abramsky O.
J Neuroimmunol. 1992 Aug;39(3):201-10.
PMID: 1644896 [PubMed – indexed for MEDLINE]


16: Prevention of experimental autoimmune encephalomyelitis and induction of tolerance with acute immunosuppression followed by syngeneic bone marrow transplantation.
Karussis DM, Slavin S, Lehmann D, Mizrachi-Koll R, Abramsky O, Ben-Nun A.
J Immunol. 1992 Mar 15;148(6):1693-8.
PMID: 1541813 [PubMed – indexed for MEDLINE]


USA puppy

And then you have stem cell in the USA……….The Stem Cell puppy says:

“Hmmmmmm………Let me lie down and think about this……….How much money is this going to make me?”


This is going to work. Be Well,